This review evaluated the efficacy and safety of carbetocin for prophylactic management of the third stage of labour and concluded that it was probably as effective as oxytocin or syntometrine, but that further research is needed. Due to limitations in the review methods a cautious interpretation of the results is recommended.
Study selection
Clinical trials that compared carbetocin administered intravenously or intramuscularly as part of active management of the third stage of labour with placebo, oxytocin or a mixture of oxytocin and ergometrine were eligible for inclusion. Outcomes of interest were blood loss, uterine tone, amount and type of lochia, fundal position, adverse effects, vital signs, haemoglobin or haemocrit levels before delivery compared with 24 to 48 hours after delivery, need for additional uterotonic therapy and/or uterine massage and duration of the third stage of labour. Postpartum haemorrhage (PPH) was defined as blood loss 500mL or more and severe PPH as a loss of 1,000mL or more.
Included studies were of women who underwent vaginal deliveries (mostly singleton pregnancies) or scheduled caesarean sections under epidural or regional anaesthetic. Carbetocin was delivered intravenously as a 100μg bolus preceded or followed by saline solution and compared with a 2.5, 5 or 10 IU oxytocin bolus followed by a higher dose or saline infusion.
